WASHINGTON, D.C. — According to the CDC, more than 165 million Americans have received their first dose of the COVID-19 vaccine, which amounts to 32 percent of the population.
On Monday, a new study was released which suggests receiving one dose of Pfizer’s vaccine is as good as getting two doses, but only for people who have previously been infected with Coronavirus.
Researchers explain people who have recovered from COVID-19, have a strong immune response from one dose, as the general population receives two doses.
The research team monitored antibody levels of more than 1,000 healthcare workers in the Cedar-Sinai Health System who have received the Pfizer vaccine.
The team also surveyed workers about previous COVID-19 infections.
The study found people who have recovered from the Coronavirus had similar immune responses after one vaccine dose as those who never had COVID-19, and had been given two doses.
The findings also support previous research, which indicated vaccination boosts the effect of the immune responses to natural infection. The findings could also potentially stretch the vaccine supply.
If people with previous COVID-19 infections only need one dose, that would allow others to get vaccination more quickly.
TRENDING NOW:
Cox Media Group
/cloudfront-us-east-1.images.arcpublishing.com/cmg/XCUXZC2XYZHCRGNNGKFEX6U3LQ.png)
